Clinical Research Division, and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, University of Washington School of Medicine, Department of Pharmacy, University of Washington School of Medicine, and Department of Pharmacy, Seattle Cancer Care Alliance, Seattle, WA.
Clinical Research Division, and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, University of Washington School of Medicine, Department of Pharmacy, University of Washington School of Medicine, and Department of Pharmacy, Seattle Cancer Care Alliance, Seattle, WA.
Semin Hematol. 2018 Oct;55(4):185-188. doi: 10.1053/j.seminhematol.2017.07.004. Epub 2017 Sep 21.
High out-of-pocket (OOP) spending on cancer drugs is a known contributor to "financial toxicity" among cancer patients. Many predict that this problem will only worsen as patients continue to bear more responsibility for the cost of their medical care and as the use of oral chemotherapeutic agents increases. Although foundations and pharmaceutical companies offer patient assistance programs (PAPs) to improve drug affordability, the degree to which these programs are used is poorly understood. There are several barriers to the use of PAPs that not only affect access to patients who may benefit but also create limitations on the research and study of these programs.
癌症药物的高额自付费用是导致癌症患者“财务毒性”的已知因素。许多人预测，随着患者继续承担更多医疗费用的责任，以及口服化疗药物的使用增加，这个问题只会变得更糟。尽管基金会和制药公司提供患者援助计划（PAP）来提高药物的可负担性，但这些计划的使用程度还不太清楚。PAP 的使用存在一些障碍，这些障碍不仅影响了可能受益的患者的获得，也对这些计划的研究和研究造成了限制。
